

/ / ()
/ /

MIC (ESBLs)

*

MIC
MIC

MIC *ESBLs*
MIC *CLSI*
ESBLs $\mu\text{m}/\text{ml}$
 $\mu\text{m}/\text{ml}$ *MIC*

MIC
ESBL
(n=) / *ESBLs*
ESBLs
(n=) /

MIC
MIC

ESBLs

ESBLs

ESBLs

ESBLs:

CLSI

ESBLs

(ESBL)

.()

ESBLs .()

()

.()

ESBLs

.()

ESBLs

ESBL

MIC

MIC

ESBL


.()

.()


ESBLs

ESBLs


(n=)



()



()



(/)

/


ESBL

E.coli


(n=)

/

(P⁺C⁺)






ESBL
()



ESBL
()

% MIC %
 % MIC %
 % MIC %
 .() MIC≥ % MIC
 .() MIC≥ %
 .() MIC %
 .() MIC %
 .() ESBL MIC≥ %
 .() MIC %
 .()





MIC (%)

ESBL
(ESBLs)

ESBL

.() ESBL

ESBL

.()

/ /

.()

ESBL

.()

ESBL

.()

(n=)

/ ESBLs

ESBL

/

CT E-Test DDT

DDT

E-Test	% /	CT	% /	
% /		ESBLs	% /	ESBL
()				

MICs

(n=) / (P⁺C⁻)

MIC

%

mcg/ml MIC

mcg/ml

AmpC

MIC

AmpC

()

% %

mcg/ml MIC

mcg/ml

()

α

ESBL

)

ESBL

(

()

(Breakpoint)

ESBL

ESBL

ESBLs

MIC

()

MIC

% /

ESBL

ESBLs

MIC

()

MIC≥

%

≥ mcg/ml

≥ mcg/ml

ESBLs

MIC ESBL
mcg/ml
(CLSI)

.() MIC
≥ mcg/ml ≥ mcg/ml

REFERENCES

1. Raul C. Extended-spectrum β -lactamases: a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 2005; 33: 104-7.
 2. Konthe H, Shah P, Krcmery V, Antal M, Mitsuhasi S. Transferable resistance to Cefotaxime, Cefoxitin, Cefamandole and Cefuroxime in clinical isolates of *Klebsiella pneumoniae* and

- Cefuroxim in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. Infection 1983; 11: 315-17.
3. Philippon A, Labia R, Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1989; 33: 1131-6.
 4. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-71.
 5. Blondeau JM. Extended-spectrum beta-lactamases. Semin Respir Infect 2001; 16: 169-76.
 6. Clinical and laboratory standards Institute: Performance Standards for Antimicrobial Susceptibility testing: Fifteenth Informational supplement 2005; 25(1): 100-15.
 7. Queenan AM, Foleno B, Gownloy C. Effect of inoculum and β -lactamase activity in AmpC and Extended-spectrum β -lactamases(ESBLs)-producing *Escherichia coli* and *Klebsiella pneumoniae* clinical isolates tested by NCCLS ESBL methodology. J Clin Microbiol 2004; 42(1): 269-75.
 8. Pterson DL, Bonomo RA. Extended-spectrum β -lactamases: a clinical update. Clin Microbiol Rev 2005; 18 (4):657-86.
 9. Stobberingh EE, Arends J, Hoogkamp-Korstanje JA, Goessens WH, Visser MR, Buiting AG, et al. Occurrence of extended-spectrum beta-lactamases in Dutch hospitals. Infection 1999; 27: 348-54.
 10. Branger C, Lesimple AL, Bruneu B, Berry, Lambert-Zechovsky N. Long-term investigation of the clonal dissemination of *Klebsiella pneumoniae* isolates producing extended-spectrum beta-lactamases in a university hospital. J Med Microbiol 1998; 47: 209-10.
 11. Bradford PA. Extended-spectrum β -lactamases in the 21st century: characterisation, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14 (4): 933-51.
 12. Yagi T, Kruokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum β -lactamases in clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli* in Japan. FEMS Microbiol Lett 2000; 184: 53-6.
 13. European Antimicrobial Resistance Surveillance System Annual Report 2005, On-going surveillance of *S.pneumoniae*, *S. aureus*, *E. coli*, *E. faecalis*, *K. pneumoniae* and *P. aeruginosa*, EARSS, Bilthoven, The Netherlands, October 2006.
 14. Shah AA, Hasan F, Ahmad S, Hameed A. Characteristic epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum β -lactamases. Research in Microbiology 2004; 155: 409-21.
 15. Philippon A, Arlet G, Jacoby AG. Plasmid-determined AmpC-Type β -lactamases. Antimicrob Agents Chemother 2002; 46(1): 1-11.
 16. Bell JM, Chitsaz M, Turnidge JD, Barton M, Walters LJ, Jones RN. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of *Escherichia coli* and *Klebsiella pneumoniae*: results from the SENTRY Asia-Pacific Surveillance Program. J Clin Microbiol 2007; 45(5): 1478-82.

MIC	ESBLs
-----	-------

18. Mobaiyen H, Nahaei MR, Amirmizafari N, Moaddab SR, Hoseni F. First report of CTX-M type β -lactamases-production in clinical *Escherichia coli* isolates from intensive care units in Tabriz. 1st Iranian Congress of Clinical Microbiology. Shiraz 2007; P: 66.
19. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.